
feb pm et
summari compani one largest world-wide provid integr dialysi servic
patient suffer chronic kidney failur
price-to-earnings oper ep
risk assess reflect stabl demand dialysi
servic driven rise senior popul
off-set depend third-parti payment
includ medicar medicaid
may ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
see net revenu fall due
sale davita medic group
segment increas
view age popul activ
acquisit consolid environ
intern expans long-term growth
driver see expand number
dialysi facil howev expect loss
intern oper next
year think driver growth
eventu also see dialysi busi
face headwind declin payor mix
toward medicar medicaid less
profit commerci insur
forecast oper margin
lower dialysi reimburs rate
invest higher labor cost
longer term margin like enhanc
oper effici leverag
expand number facil well
sale medic group segment
see ep
ep growth like aid share
repurchas program billion
remain februari
encourag medicar decis
implement rate cut multi-year period
minim disrupt provid access
patient care see substanti
regulatori risk charit assist
dialysi patient akf
previous jeopard rule
mandatori disclosur insur dialysi
provid provid charit fund
premium health plan feder court later
issu injunct suspend rule
see victori dialysi compani
also view pend sale medic group
segment expect close unit
posit allow focu
core busi increas financi
flexibl buy-back de-lever
risk recommend target price
includ failur achiev cash flow
target price appli
ev/ebitda multipl
estim multipl line peer
balanc benefit stem sale
medic group expect
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview davita inc lead provid dialysi relat servic patient
suffer chronic kidney failur also known end-stag renal diseas esrd decemb
compani oper provid administr servic network outpati
dialysi center design specif outpati hemodialysi
result growth acquisit occasion becom highli leverag
opinion acquir center gambro acquisit well independ
center compani acquir center open new center sold six close
septemb acquir dsi renal ad facil led divestitur mani
dsi portfolio novemb complet merger privat held healthcar partner
physician practic network billion payabl billion cash million share
hemodialysi use artifici kidney call dialyz remov certain toxin fluid salt
patient blood togeth machin control extern blood flow monitor certain vital sign
patient periton dialysi use patient periton abdomin caviti elimin fluid
market profil esrd state advanc renal impair irrevers requir routin
dialysi treatment kidney transplant sustain life treatment option esrd includ
hemodialysi periton dialysi kidney transplant growth procedur driven
age popul increas incid rate diseas caus kidney failur
diabet hypertens lower mortal rate dialysi patient growth rate minor
popul higher-than-averag incid rate esrd assum dialysi market
 continu grow mid-singl digit rang next sever year age
popul keep long-term growth mid-singl digit rang
legal/regulatori issu govern medicar medicaid remain primari
payor care esrd dialysi patient account roughli two-third dialysi revenu
medicar account major govern revenu balanc deriv
commerci payor esrd payment rate dialysi establish congress medicar composit
rate set center medicar medicaid servic includ payment dialysi
treatment suppli use treatment specifi laboratori test certain pharmaceut
provid paid separ servic pharmaceut includ erythropoietin epo
vitamin analog iron supplement gener averag cost servic pharmaceut
plu small margin base price set medicar medicar payment rate suffici
cover averag cost provid dialysi treatment
cover treatment medicar pay amount set medicar system patient
respons remain case secondari payor cover part
financi trend averag revenu per treatment
level volatil recent year due fluctuat patient mix
commerci govern insur patient go forward expect revenu growth mid-
upper singl digit ep growth low-doubl digit expand oper
domest intern address medicar reimburs cut octob
complet billion refinanc retir debt due novemb
complet merger privat held healthcar partner physician practic network billion
payabl billion cash million share expect robust cash flow enabl rapid debt
repay addit strateg acquisit expand presenc nascent account care
market may berkshir hathaway took stake agre standstil agreement
acquir stake decemb berkshir stake
septemb complet stock split rais number share outstand
offic intern
presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued
neutral sinc februari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
time past month gather
suffici number vote pass variou
repeal replac bill believ
republican revisit futur
indic shift
attent tax reform futur potenti
repeal bill would take effect
opinion give sub-industri time
adjust mitig impact new
year-to-d septemb
increas composit
 health servic
fell vs increas
fundament outlook health care
servic sub-industri next month
neutral think servic includ
rehabilit clinic laboratori
dialysi continu benefit
favor demograph partli offset
increas pressur reduc govern
spend rais possibl medicar
reimburs rate cut possibl
repeal elimin medicaid
expans trump administr
becom neutral dialysi group
view favor patient demograph
off-set reimburs rate pressur
center medicar medicaid servic look
cut expens expect provid see
higher treatment margin due lower drug
cost util think provid
still reliant maintain
commerci base rate much higher
offer medicar think
age popul increas focu
prevent care benefit clinic lab
think increas test per requisit
esoter test lead low singl
remain posit pharmaci benefit manag
pbm see pbm benefit
billion dollar brand drug slate
lose patent protect come year
expect republican administr
continu effort repeal
servic sub-industri larg exposur
medicaid clientel could advers
uncompens care rate could rise
hospit facil would lead
lower profit lower demand health
care servic senat fail multipl
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
laboratori corpor america
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
ep vs consensu sale increas
increas treatment volum see sale growth impact
reimburs rate pressur given limit visibl due regulatori
uncertainti surround futur maintain hold opinion /k
davita inc announc appoint robert lang presid
intern busi lang join bupa season execut
intern experi span europ middl east asia latin
america lang recent led bupa intern market busi
follow tenur bank insur ub hsbc manag
director bupa global lang oversaw compani
intern privat medic insur oper global led strateg
expans china india brazil saudi arabia unit arab emir
march roger valin member board director
davita inc sinc notifi board plan retir
board therefor stand re-elect compani annual
meet stockhold held june mr valin indic
intent continu serv director compani expir
current term annual meet
davita kidney divis davita inc welcom francesca tentori md
mcsi medic director outcom research member offic
chief medic offic physician leadership team dr tentori
member american societi nephrolog compar effect task
forc well american associ kidney patient medic advisori
board dr tentori current adjunct instructor medicin vanderbilt
davita kidney appoint adam weinstein vice presid medic
affair within offic chief medic offic dr weinstein
extens background health care polici regul well
wide-spread knowledg bring unparallel expertis allen
nissenson facp chief medic offic davita kidney
uniqu combin allow dr weinstein work directli clinic
close support physician electron health record team prior
work dr weinstein work privat practic also
work vice presid univers maryland-shor region
analyst research note compani news
rais target price appli
ev/ebitda multipl estim line peer
balanc reimburs rate pressur expect benefit
sale medic group segment increas ep estim
set report oper ep
vs line consensu sale increas aid
growth treatment per day expect experi margin pressur
driven increas labor cost flat reimburs rate /keith
februari carol anthoni john davidson member board
director inc sinc notifi compani plan
retir board march
et cfra keep buy opinion share group
agre acquir davita medic group physician
group believ deal fit well
strategi expand optum unit includ primari
urgent ambulatori care davita medic oper clinic urgent
care center half-dozen outpati surgic center medic staff
six state see million patient note unit post
loss think leverag overlap certain area
includ cost synergi improv unit profit /jeffrey
et cfra keep hold opinion share inc
enter definit agreement
sell davita medic group dmg segment billion cash dmg
oper nearli clinic well urgent care center six
outpati surgic center pend transact subject regulatori
approv customari close condit expect close
see pend deal posit allow focu
core kidney dialysi busi increas financi flexibl
buyback de-lever strateg opportun /danni yang cfa
maintain target price appli ev/ebitda
multipl estim line peer balanc
stabl sale growth outlook expect margin compress lower
reimburs rate partial off-set cost reduct effort trim
ep estim
report oper ep vs consensu
sale increas growth medic segment expect
sale growth aid modest volum increas /keith snyder
keep target appli ev/ebitda multipl
estim slight discount five-year
histor averag reflect slow long-term sale earn
growth outlook keep ep estim trim
report oper ep
vs consensu total sale increas driven
growth medic group segment expect sale growth
volum growth partial off-set declin
rais target ev/ebitda
multipl estim discount peer reflect
slower revenu growth outlook trim ep
estim report oper
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
